Recombinant PLAP antibody (full length)

Catalog No. ABIN7878810

The Mouse Monoclonal anti-PLAP antibody is suitable to detect PLAP in samples from Human. It has been validated for WB and IHC (p).

Quick Overview for Recombinant PLAP antibody (full length) (ABIN7878810)

Target: PLAP (ALPP) (Placental Alkaline Phosphatase (ALPP))

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This PLAP antibody is un-conjugated

Application: Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Clone: RALP-870

Product Details anti-PLAP Antibody

Binding Specificity: full length

Purpose: Recombinant ALPP Antibody / Placental Alkaline Phosphatase

Purification: Protein A/G affinity

Immunogen: Recombinant full-length human ALPP protein was used as the immunogen for the recombinant ALPP antibody.

Isotype: IgG1, kappa

Application Details

Application Notes: Optimal dilution of the recombinant ALPP antibody should be determined by the researcher.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 0.2 mg/mL

Buffer: 0.2 mg/mL in 1X PBS with 0.1 mg/mL BSA (US sourced), 0.05 % sodium azide

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: -20 °C

Storage Comment: Aliquot the recombinant ALPP antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.

Target Details for PLAP

Target: PLAP (ALPP) (Placental Alkaline Phosphatase (ALPP))

Alternative Name: ALPP

Background: Reacts with a 70 kDa membrane-bound isozyme (Regan and Nagao type) of Placental Alkaline Phosphatase (PLAP) occurring in the placenta during the 3rd trimester of gestation. It is highly specific for PLAP and shows no cross-reaction with other isozymes of alkaline phosphatase. Anti-PLAP reacts with germ cell tumors and can discriminate between these and other neoplasms. Somatic neoplasms e.g. breast, gastrointestinal, prostatic, and urinary cancers may also immunoreact with antibodies to PLAP. Anti-PLAP positivity in conjunction with anti-keratin negativity favors seminoma over carcinoma. Germ cell tumors are usually anti-keratin positive, but they regularly fail to stain with anti-EMA, whereas most carcinomas stain with anti-EMA. Anti-PLAP has been useful in the diagnosis of gestational trophoblastic disease.

UniProt: P05187